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Ten 2-substituted quinoline alkaloids isolated from a plant used for treatment of New World cutaneous 
leishmaniasis have antileishmanial in vitro activities against the extracellular forms of Leishmania spp. BALB/c 
mice infected with Leishinania amazonensis PH8 or H-142 or Leishïnaniu venezuelensis were treated 1 day after 
the parasitic infection with a quinoline alkaloid (100 mg/kg of body weight per day) or with reference drug 
N-methylglucamine antimonate (Glucantime) (56 mg of pentavalent antimony [Sb”] per kg per day) for 14 days. 
Lesion development was the criterium used to assess disease severity. Two three-carbon chain quinolines 
[2-ïi-propylquinoline and 2-(lr,2’-trans-epoqpropyl)quinoline (chimanine D)] were more potent than N-meth- 
ylglucamine antimonate against L. aïnuzonensis PH8, and five quinoline alkaloids [2-(3,4-methylenedioxyphe- 
nylethyl)quinoline, cusparine, 2-(3,4-dimethoqphenylethyl)quinoline, 2-(E)-prop-l’-enylquinoline (chimanine 
B), and skimmianine] were as effective as the reference drug. Single treatment near the site of infection, 14 days 
after infection with L. ainazonensis, with 2-n-propylquinoline or chimanine B reduced the severity of lesions but 
less notably than N-methylglucamine antimonate. 2-ïi-Propylquinoline exhibited significant activity against the 
virulent strain L. venezueleïisis. The active products did not show any apparent toxicities during the 
experiment. This study is, to our knowledge, the first to show the activity of 2-substituted quinoline alkaloids 
for experimental treatment of New World cutaneous leishmaniasis. Further investigations of these compounds 
might yet prove helpful for the development of new antileishmanial drugs. 
Cutaneous leishmaniasis and mucocutaneous leishmania- 
sis are endemic diseases in South America, particularly in 
the sub-Andean areas of the humid lowlands of Bolivia. 
Leishmaniasis is initiated by inoculation of Leishmania 
species into the skin during sand fly bites. Drugs currently 
used to cure leishmaniasis are derivatives of pentavalent 
antimony (Sb”) (sodium stibogluconate [Pentostam] and 
N-methylglucamine antimonate [Glucantime]); pentamidine, 
and amphotericin B (14). These drugs are potentially toxic 
and generally administered via the parenteral route in a 
hospital setting for relatively long periods (3). In the endemic 
regions of Bolivia, the classic treatments are too expensive 
or unavailable to the population suffering from cutaneous 
leishmaniasis (espundia). The impact of this disease was 
accentuated in sub-Andean tropical areas by the influx of 
people descending from higher areas. In Bolivia, the Insti- 
tuto Boliviano de Biologia de Altura and the French Institute 
of Scientific Research for the Development in Cooperation 
(ORSTOM) have initiated and developed original investiga- 
tions of alternative compounds for the treatment of leishma- 
niasis. In previous studies (7), we have described ìhe in vitro 
activity against the promastigote forms of Leishinania spe- 
cies and the isolation and chemical characterization of active 
compounds (8, 9) from a Bolivian plant used locally for 
treatment of cutaneous leishmaniasis and identified as Gali- 
pea longiflora Krause of the Riitaceae family. These active 
products were identified spectroscopically as 12 2-substi- 
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tuted quinoline alkaloids. The aims of this study were to 
evaluate and demonstrate the activities of these quinoline 
alkaloids in BALB/c mice infected with New World strains 
causing cutaneous leishmaniasis. We have used two isolates 
of Leislznzaiaiu amazonensis (MHOM/IFLA/B4/67/PHS and 
MHOM/GF/S4/CAY-H-142) with different degrees of infec- 
tivity and a virulent strain from Venezuela, Leishmania 
venemelensis, producing severe lesions in human infection 
(notably single and multiple cutaneous lesions) (4, 10) and 
rapid growth of lesions. The mouse footpad infection has 
been used as a model for the experiments (1, 6), and 
N-methylglucamine antimonate has been used as a reference 
drug. 
MATERIALS AND METHODS 
Chemicals. The 2-substituted quinoline alkaloids were 
isolated from the root barks, stem barks, and leaves of G. 
longiflora by fractionation and purification monitored by 
bioassay, as previously described (7), using chromato- 
graphic methods. Physical and spectral data (proton mag- 
netic resonance and mass spectrometry) were used to deter- 
mine the chemical structures of the compounds (8, 9). The 
structures of these products are shown in Fig. 1. N-methyl- 
glucamine antimonate with a pentavalent antimony (Sb’) 
content of 28% by weight was purchased from Rhône- 
Poulenc, Paris, France. 
Mice. Female and male BALB/c mice were supplied by the 
Charles Rivers Breeding Laboratory and bred at Instituto 
Boliviano de Biologia de Altura, La Paz, Bolivia. Mice 
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FIG. 1. Structures of 2-substituted quinoline alkaloids. 1, 
4-methoxy-2-phenylquinoline; 2, 2-(3,4-methylenedioxyphenyleth- 
y1)quinoline; 3, 2-n-propylquinoline; 4, 4-methoxy-2-n-pentylquino- 
line; 5, chimanine A; 6, cusparine; 7, 2-(3,4-dimethoxyphenyleth- 
y1)quinoline; 8, skimmianine; 9, chimanine B; 10, chimanine D. 
weighed between 18 and 20 g and were S weeks old when 
experiments were initiated. 
Parasites. L. amazonensis MHOM/IFLA/BR/67/PHS and 
MHOM/GF/84/CAY-H-142 and L. venezuelensis MHOM/ 
VE/74/PM-H3 were used. The source and history of the L. 
venezuelensis isolate has been previously described (4). All 
strains were maintained by passage every 6 to 8 weeks in 
hamsters. BALB/c mice ( 1 2 ,  10, 8, or 6) were infected 
subcutaneously in the right rear footpad with lo6 amastigotes 
obtained from donor hamsters. The parasites were delivered 
in 200 pl of phosphate-buffered saline (PBS). 
The growth of lesions was determined weekly by measur- 
ing the diameters of both rear feet with a direct-reading 
vernier caliper (Kroelin lODI 00T6). The size of the lesion in 
millimeters (index of leishmaniasis) was calculated by sub- 
tracting the measurement of the uninfected foot from that of 
the infected foot. Measurements commenced 1 day prior to 
the inoculation of amastigotes and were continued for 8 or  9 
weeks. For each experiment, the mean and standard error of 
the mean were calculated. 
Drug treatment. Two experiments were conducted. Mice 
in the first experiment were treated by the subcutaneous 
route. N-Methylglucamine antimonate was given at a dose of 
56 mg of Sb' per kg of body weight daily, and 2-substituted 
quinoline alkaloids were given at 100 mdkg daily. The 
quinoline alkaloids were dissolved in 40 pl of polysorbate 
(Tween 80; Prolabo). N-Methylglucamine antimonate was 
dissolved in PBS, and untreated mice received PBS and 
Tween 80. Drug treatment commenced 1 day after the 
inoculation of amastigotes and was continued once daily for 
14 days. 
In the second experiment, mice were treated directly on 
the infected rear footpad with a single dose 14 days after the 
inoculation of parasites. For this experiment, mice were 
treated withN-methylglucamine antimonate at 112 mg of Sb" 
per kg and with quinoline alkaloids at 200 mgkg. 
RESULTS 
Treatment (14 days) of mice infected with L. amazonensis 
PHS. Table 1 shows the antileishmanial data for 10 2-substi- 
tuted quinoline alkaloids given for 14 days to BALB/c mice 
infected with L. amazonensis PHS. As previously described, 
the use of either N-methylglucamine antimonate or any other 
drug had no preventive drug action on the development of 
lesions but reduced their severity (6). Preliminary toxicolog- 
ical evaluations of quinoline alkaloids given to BALB/c mice 
indicated that the drugs had reasonable therapeutic indices, 
with an acute intraperitoneal 50% lethal dose greater than 
400 mg/kg. No apparent signs of drug toxicity, weight loss, 
or hair loss were observed in any experiment; only an 
TABLE 1. Fourteen-day-treatment effects of N-methylglucamine antimonate and 10 2-substituted quinoline alkaloids 
on the development of L. amazonensis PH8 in BALB/c mice 
Lesion diam (mm)b the following no. of wk postinfection: 
2 4 6 8 
Drug" 
4-Methoxy-2-phenylquinoline (1) 0.50 f 0.08 1.27 f 0.21 3.77 f 0.36 5.01 f 0.50 
2-(3,4-Methylenedioxyphenylethyl)quinoline (2) 0.46 f 0.10 0.83 f 0.16 3.10 k 0.40 4.62 f 0.48 
2-n-Propylquinoline (3) 0.48 r 0.11 0.72 f 0.18 2.10 k 0.35 3.42 f 0.26 
4-Methoxy-2-n-pentylquinoline (4) 0.40 f 0.09 1.16 f 0.13 3.61 f 0.41 4.94 f 0.51 
Chimanine A (5) 0.47 f 0.19 1.83 f 0.36 3.54 f 0.69 4.88 f 0.67 
Cusparine (6) 0.62 f 0.11 1.12 f 0.26 2.85 f 0.45 4.15 f 0.68 
2-(3,4-Dimethoxyphenylethyl)quinoline (7) 0.33 f 0.11 0.82 f 0.17 3.21 f 0.34 4.44 f 0.60 
Skimmianine (8) 0.36 f 0.08 1.26 f 0.33 2.93 f 0.41 4.25 f 0.48 
Chimanine B (9) 0.35 f 0.11 0.92 k 0.28 2.35 f 0.40 4.39 f 0.50 
Chimanine D (10) 0.35 f 0.08 1.04 f 0.29 1.68 k 0.43 2.60 f 0.66 
N-Methylglucamine antimonateC 0.17 f 0.07 0.48 f 0.15 2.35 f 0.34 4.02 f 0.41 
None 0.53 f 0.14 1.25 f 0.16 3.80 r 0.41 6.60 2 0.67 
LI Given for 14 days starting 1 day after the inoculation of L. amazonensis. Dosages: N-methylglucamine, 56 mg of Sb" per kg per day; all other drugs, 100 
Calculated by subtracting the measurement for the uninfected footpad from the measurement for the infected footpad. The data are means 3 standard errors 
Standard drug. 
mg/kg/day. Numberrs in parentheses refer to structures depicted in Fig. 1. 
of the means for groups of 10 mice each. 
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FIG. 2. Effects of chimanine D (100 mg/kg/day) and N-methyl- 
glucamine antimonate (Glucantime) (56 mg of Sb" per kg per day) on 
the development of L. antazoizensis PH8 in BALB/c mice. Treat- 
ments were given for 14 days, commencing 1 day after inoculation 
with L. ainazoizeizsis. Datum points represent the average measure- 
ments for groups of 10 mice each. Lesion diameter was expressed as 
the thickness of the infected footpad minus the thickness of the 
contralateral uninfected footpad. Bars, standard errors of the 
means. 
inflammatory effect near the site of administration of the 
drug was observed. Two quinoline alkaloids, 2-iz-propylqui- 
noline and chimanine D (Fig. 1, compounds 3 and 10, 
respectively, and Fig. 2), were more active than the refer- 
ence antileishmanial drug, N-methylglucamine antimonate, 
after the 8 weeks of the experiment. Both compounds are 
three-carbon chain 2-substituted quinolines with a propyl 
group and a propyl traits-epoxy-1'2' group, respectively. 
The following five quinoline alkaloids were approximately as 
effective as N-methylglucamine antimonate in this model: 
three substituted 2-phenylethyl compounds [2-(3,4-methyl- 
enedioxyphenylethyl)quinoline, cusparine and 2-(3,4-di- 
methoxyphenylethy1)quinoline (Fig. 1, compounds 2, 6, and 
7, respectively)], a furo(2,3,b)quinoline alkaloid, skimmian- 
ine (Fig. 1, compound S), and a three-carbon chain 2-substi- 
tuted quinoline, chimanine B (Fig. 1, compound 9). The 
following three compounds exhibited moderate activities: 
4-methoxy-2-phenylquinoline, 4-methoxy-2-ia-pentylquino- 
line, and chimanine A (or 4-methoxy-2-it-propylquinoline) 
(Fig. 1, compounds 1, 4, and 5 ,  respectively). The presence' 
of a 4-methoxy group in these alkaloids produced a decrease 
in antileishmanial activity. 
Treatment (14 days) of mice infected with L. amazonensis 
H-142. The effects of four quinoline alkaloids and N-meth- 
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FIG. 3. Effects of 2-12-propylquinoline (100 mg/kg/day) and N- 
methylglucamine antimonate (Glucantime) (56 mg of Sb' per kg per 
day) on the development of L. ainazonerzsis H-142 in BALB/c mice. 
Treatments were given for 14 days, commencing 1 day after inocu- 
lation with L. amazonensis. Datum points represent the average 
measurements for groups of 10 mice each. Lesion diameter was 
expressed as the thickness of the infected footpad minus the 
thickness of the contralateral uninfected footpad. Bars, standard 
errors of the means. 
ylglucamine antimonate on the development of L. arnazon- 
eizsis H-142-caused lesions in mice are presented in Table 2. 
After S weeks, treatment with 2-n-propylquinoline (Fig. 1, 
structure 3) was as effective as that with the reference drug 
(Fig. 3). The remaining compounds, 2-(3,4-methylenediox- 
yphenylethyl)quinoline, chimanine A, and cusparine (Fig. 1, 
compounds 1, 5 ,  and 6, respectively), did not exhibit any 
effect. With this model, we have noted a slow development 
of lesion growth in each group of mice. The difference 
between the diameters of the lesions in the untreated mice 
and the diameters of the lesions in those mice treated with 
N-methylglucamine antimonate was only 1 mm. After 9 or 10 
weeks, we observed a beginning of ulceration of lesions 
followed by autocicatrization in the untreated mice. 
Single treatments on the footpads of mice infected with L. 
amazonensis PHS. In this experiment, the treatments were 
administered at the site of parasitic infection. The results 
obtained are shown in Table 3. Each of the two 2-substituted 
three-carbon chain compounds 2-it-propylquinoline and chi- 
manine B [or 2-(E)-prop-l'-enylquinoline] (Fig. 1, com- 
pounds 3 and 9, respectively) reduced the severity of lesions 
in this model but to a lower extent than the standard 
antimony treatment, which appeared to be much more 
effective. The following four quinoline alkaloids did not 
TABLE 2. Fourteen-day-treatment effects of N-methylglucamine antimonate and three 2-substituted quinoline alkaloids 
on the development of L. amazoizensis H-142 in BALB/c mice 
Druf 
Lesion diam (mm)b the following no. of wk postinfection: 
2 4 6 9 
2-(3,4-Methylenedioxyphenylethyl)quinoline (2) 0.35 f 0.11 0.97 f 0.13 1.42 .t 0.22 2.65 & 0.42 
Chimanine A (5) 0.46 f 0.10 0.61 & 0.15 1.01 f 0.21 2.80 f 0.52 
Cusparine (6) 0.43 t- 0.04 0.73 2 0.07 1.04 t- 0.36 2.96 f 0.58 
N-Methylglucamine antimonate' 0.42 .t 0.10 0.67 2 0.18 0.66 & 0.24 1.98 & 0.34 
None 0.53 f 0.12 0.88 t- 0.12 1.43 2 0.44 2.96 f 0.46 
a See Table 1, footnote a. 
See Table 1, footnote b. 
Standard drug. 
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TABLE 3. Single-administration effects of N-methylglucamine antimonate and six 2-substituted quinoline alkaloids 
on the development of L. amazonensis PH8 in BALB/c mice 
Drug" 
Lesion diam (mm)h the following no. of wk postinfection: 
2 4 6 8 
2-(3,4-Methylenedio~phenylethyl)quinoline (2) 0.40 f 0.18 1.20 f 0.19 2.71 f 0.48 5.22 f 0.78 
2-n-Propylquinoline (3) 0.45 f 0.12 1.41 f 0.31 2.37 f 0.65 3.68 f 0.84 
Cusparine (6) 0.37 -t- 0.12 1.27 f 0.31 2.90 f 0.62 5.03 f 0.77 
Skimmianine (8) 0.38 f 0.04 1.51 f 0.35 2.95 f 0.36 4.98 f 0.36 
Chimanine B (9) 0.28 f 0.07 1.75 f 0.57 1.78 f 0.52 3.67 f 0.82 
Chimanine D (10) 0.38 f 0.08 1.40 f 0.18 2.65 f 0.47 4.90 f 0.72 
2.83 f 0.58 N-Methylglucamine antimonateC 0.45 f 0.06 0.53 f 0.23 
None 0.35 f 0.08 
1.52 f 0.38 
1.01 f 0.20 2.87 f 0.29 ' 4.90 f 0.42 
a Single administration on the infected rear footpad 14 days after the inoculation of L. amazonensis. Doses: N-methylglucamine antimonate, 112 mg of Sbv per 
standard errors 
kg; all other drugs, 200 mglkg. Numbers in parentheses refer to structures depicted in Fig. 1. 
of the means for groups of six mice each. 
Calculated by subtracting the measurement for the uninfected footpad from the measurement for the infected footpad. The data are means 
Standard drug. 
show any effect: 2-(3,4-methylenedioxyphenylethyl)quino- 
line (Fig. 1, compound 2), cusparine (compound 6), a furo- 
quinoline alkaloid, skimmianine (compound 8), and the most 
active product in the first experiment (14-day treatment), 
chimanine D (compound 10). 
Treatment of L. venezuelensis infection. With the virulent 
strain L. venezuelensis, two quinoline alkaloids, 2-(3,4- 
methylenedioxyphenylethy1)quinoline and 2-n-propylquino- 
line (Fig. 1, compounds 2 and 3, respectively), have been 
tested. The results obtained with this model are presented in 
Table 4. After 8 weeks, the substituted 2-propyl chain 
compound (Fig. 1, compound 3) was as effective as the 
reference drug and showed the same inhibitory effect as that 
against L. amazonensis. Some untreated BALB/c mice 
infected with L. venezuelensis presented multiple cutaneous 
nodules on the ears. 
DISCUSSION 
The data collected in this work indicate that L. amazon- 
ensis is reasonably susceptible to 2-substituted three-carbon 
chain quinoline alkaloids (2-n-propylquinoline and chima- 
nine D [Fig. 1, compounds 3 and 10, respectively]) and 
2-substituted aryl quinoline alkaloids. Substitution at posi- 
tion 4 of the quinoline by the methoxy group (Fig. 1, 
compounds 1, 4, and 5) results in decreased antileishmanial 
activity. We have observed remarkable bioavailabilities of 
oily quinoline alkaloids (2-substituted three-carbon chain 
and 2-phenylethyl quinolines) not exhibited by cristalline 
compounds such as 4-methoxy-2-phenylquinoline (Fig. 1, 
compound 1). Results of the in vivo experiments indicated 
that all mice treated with 100 mg of a 2-substituted quinoline 
alkaloid per kg daily for 14 days resisted infection with each 
New World cutaneous leishmaniasis-causing strain, includ- 
ing the virulent strains L. amazonensis PH8 and L. venezu- 
elensis H-3. The high concentration of a 2-substituted quin- 
oline alkaloid did not cause any obvious toxicity in the mice 
even at a dosage of 100 mg/kgJday for 14 days. In previous 
experiments, treatments with antimony drugs at 28 and 56 
mg of Sb" per kg per day for 1 week did not produce any 
significant difference between the untreated and treated 
mice. In general, all the 2-substituted quinoline alkaloids 
tested exhibited a minimal activity (50 to 100 pdml) against 
five strains of promastigote forms of Leishmania spp. and 
five clones of epimastigote forms of Typanosoma cmzi (7). 
It is often difficult to correlate drug activity in vitro with that 
in vivo (3). Traditional use of G. 1ongiJor;a in areas of 
endemic cutaneous leishmaniasis together with our clinical 
observations facilitated excellent evaluation of the efficacies 
of these active compounds. 
Many aminoquinoline compounds, substituted at positions 
8, 7, 6 and 4, have been synthesized at the Walter Reed 
Army Institute for Research and have previously been 
shown to be effective against cutaneous leishmaniasis and 
visceral leishmaniasis (11-13, 15), malaria (5), and recently, 
against Pneunzocystis carinii-caused pneumonia (2). An ex- 
amination of the data obtained in the present study demon- 
strates that interesting biological activities also exist in the 
2-substituted quinoline alkaloids. 
To our knowledge, this study is the first to show the 
activities of 2-substituted quinoline alkaloids for treating 
TABLE 4. Effects of N-methylglucamine antimonate and three 2-substituted quinoline alkaloids on the development 
of L. venezuelensis H-3 io BALB/c mice 
Lesion diam the following no. of wk postinfection: 
Drug" 
2 4 6 8 
2-(3,4-MethyIenedio~phenylethyl)quinoline (2) 0.60 f 0.26 1.80 f 0.44 3.78 f 0.49 5.50 f 0.55 
2-n-Propylquinoline (3) 0.33 f 0.15 1.26 f 0.21 2.68 f 0.39 4.12 f 0.76 
N-Methylglucamine antirnonate' 0.45 f 0.19 0.95 f 0.21 2.48 f 0.34 4.25 f 0.44 
None 0.61 f 0.30 2.07 f 0.19 4.12 f 0.22 6.60 f 0.51 
LI Given for 14 days starting 1 day after the inoculation of L. venezuelensis. Dosages: N-methylglucamine antimonate, 56 mg of Sb" per kg per day; all other 
Calculated by subtracting the measurement for the uninfected footpad from the measurement for the infected footpad. The data are means % standard errors 
Standard drug. 
drugs, 100 mglkglday. Numbers in parentheses refer to structures depicted in Fig. 1. 
of the means for groups of six mice each. 
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experimental New World cutaneous leishmaniasis. The ac- 
tivities of 2-substituted quinoline alkaloids against other 
strains causing New World cutaneous leishmaniasis or vis- 
ceral leishmaniasis may be demonstrated with oral treat- 
ments of mice susceptible to Leislzinania spp. The total 
synthesis of the compounds tested in this work together with 
other derived quinoline alkaloids is in progress in our labo- 
ratory. Following studies on the structure-activity relation- 
ship, we hope to improve the effectiveness of 2-substituted 
quinoline alkaloids for the treatment of cutaneous leishma- 
niasis. 
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